Adenike O. Adekeye
Low-Density Lipoprotein Pathway Is a Ubiquitous Metabolic Vulnerability in High Grade Glioma Amenable for Nanotherapeutic Delivery
Adekeye, Adenike O.; Needham, David; Rahman, Ruman
Authors
Professor DAVID NEEDHAM David.Needham@nottingham.ac.uk
PROFESSOR OF TRANSLATIONAL THERAPEUTICS
Professor Ruman Rahman RUMAN.RAHMAN@NOTTINGHAM.AC.UK
PROFESSOR OF MOLECULAR NEURO-ONCOLOGY
Abstract
Metabolic reprogramming, through increased uptake of cholesterol in the form of low-density lipoproteins (LDL), is one way by which cancer cells, including high grade gliomas (HGG), maintain their rapid growth. In this study, we determined LDL receptor (LDLR) expression in HGGs using immunohistochemistry on tissue microarrays from intra- and inter tumour regions of 36 adult and 133 paediatric patients to confirm LDLR as a therapeutic target. Additionally, we analysed expression levels in three representative cell line models to confirm their future utility to test LDLR-targeted nanoparticle uptake, retention, and cytotoxicity. Our data show widespread LDLR expression in adult and paediatric cohorts, but with significant intra-tumour variation observed between the core and either rim or invasive regions of adult HGG. Expression was independent of paediatric tumour grade or identified clinicopathological factors. LDLR-expressing tumour cells localized preferentially within perivascular niches, also with significant adult intra-tumour variation. We demonstrated variable levels of LDLR expression in all cell lines, confirming their suitability as models to test LDLR-targeted nanotherapy delivery. Overall, our study reveals the LDLR pathway as a ubiquitous metabolic vulnerability in high grade gliomas across all ages, amenable to future consideration of LDL-mediated nanoparticle/drug delivery to potentially circumvent tumour heterogeneity.
Citation
Adekeye, A. O., Needham, D., & Rahman, R. (2023). Low-Density Lipoprotein Pathway Is a Ubiquitous Metabolic Vulnerability in High Grade Glioma Amenable for Nanotherapeutic Delivery. Pharmaceutics, 15(2), Article 599. https://doi.org/10.3390/pharmaceutics15020599
Journal Article Type | Article |
---|---|
Acceptance Date | Feb 9, 2023 |
Online Publication Date | Feb 10, 2023 |
Publication Date | 2023-02 |
Deposit Date | Feb 22, 2023 |
Publicly Available Date | Feb 23, 2023 |
Journal | Pharmaceutics |
Electronic ISSN | 1999-4923 |
Publisher | MDPI |
Peer Reviewed | Peer Reviewed |
Volume | 15 |
Issue | 2 |
Article Number | 599 |
DOI | https://doi.org/10.3390/pharmaceutics15020599 |
Keywords | low-density lipoprotein, high grade glioma, perivascular, nanotherapy |
Public URL | https://nottingham-repository.worktribe.com/output/17386197 |
Publisher URL | https://www.mdpi.com/1999-4923/15/2/599 |
Files
pharmaceutics-15-00599
(3.3 Mb)
PDF
Publisher Licence URL
https://creativecommons.org/licenses/by/4.0/
You might also like
Radiogenomics as an Integrated Approach to Glioblastoma Precision Medicine
(2024)
Journal Article
Downloadable Citations
About Repository@Nottingham
Administrator e-mail: discovery-access-systems@nottingham.ac.uk
This application uses the following open-source libraries:
SheetJS Community Edition
Apache License Version 2.0 (http://www.apache.org/licenses/)
PDF.js
Apache License Version 2.0 (http://www.apache.org/licenses/)
Font Awesome
SIL OFL 1.1 (http://scripts.sil.org/OFL)
MIT License (http://opensource.org/licenses/mit-license.html)
CC BY 3.0 ( http://creativecommons.org/licenses/by/3.0/)
Powered by Worktribe © 2024
Advanced Search